Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dr Reddys Laboratories (RDY) Non-Current Deferred Tax Liability (2016 - 2025)

Historic Non-Current Deferred Tax Liability for Dr Reddys Laboratories (RDY) over the last 13 years, with Q3 2025 value amounting to $169.9 million.

  • Dr Reddys Laboratories' Non-Current Deferred Tax Liability rose 292.16% to $169.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $169.9 million, marking a year-over-year increase of 292.16%. This contributed to the annual value of $165.0 million for FY2025, which is 140000.0% up from last year.
  • Per Dr Reddys Laboratories' latest filing, its Non-Current Deferred Tax Liability stood at $169.9 million for Q3 2025, which was up 292.16% from $162.9 million recorded in Q1 2025.
  • In the past 5 years, Dr Reddys Laboratories' Non-Current Deferred Tax Liability registered a high of $169.9 million during Q3 2025, and its lowest value of $576967.1 during Q3 2022.
  • For the 5-year period, Dr Reddys Laboratories' Non-Current Deferred Tax Liability averaged around $52.8 million, with its median value being $7.4 million (2021).
  • As far as peak fluctuations go, Dr Reddys Laboratories' Non-Current Deferred Tax Liability plummeted by 8278.67% in 2022, and later soared by 1328220.42% in 2024.
  • Dr Reddys Laboratories' Non-Current Deferred Tax Liability (Quarter) stood at $1.3 million in 2021, then tumbled by 56.82% to $576967.1 in 2022, then soared by 113.86% to $1.2 million in 2023, then soared by 13282.2% to $165.1 million in 2024, then grew by 2.92% to $169.9 million in 2025.
  • Its Non-Current Deferred Tax Liability was $169.9 million in Q3 2025, compared to $162.9 million in Q1 2025 and $165.1 million in Q3 2024.